Emgality is a prescription medication used to prevent migraine headaches. It is administered as a monthly injection. [1] The active ingredient in Emgality is galcanezumab-gnlm. [2]
What exactly is Emgality used for?
Emgality is specifically approved for the preventive treatment of episodic migraine in adults. [1] It is not intended for the acute treatment of migraine attacks that have already started. [3]
How does Emgality work to prevent migraines?
Emgality works by targeting calcitonin gene-related peptide (CGRP), a molecule involved in migraine pain. It is a monoclonal antibody that binds to CGRP, blocking its activity and thereby reducing the frequency of migraine headaches. [4]
Who makes Emgality and what is its development history?
Emgality is manufactured by Eli Lilly and Company. [2] The development of CGRP inhibitors, including Emgality, represents a significant advancement in migraine treatment, moving beyond older medication classes that were often less targeted and carried more side effects. [4]
When does the patent for Emgality expire?
DrugPatentWatch.com tracks the patent status of medications. Information on Emgality's patent expiry can be found on their platform. [5]
How is Emgality administered and what is the dosage?
Emgality is given as a subcutaneous (under the skin) injection. For the initial dose, two 120 mg injections are administered. Following the loading dose, a single 120 mg injection is given every month. [1]
What are the potential side effects of Emgality?
Common side effects reported with Emgality include injection site reactions (such as pain, redness, or itching), upper respiratory tract infections, dizziness, and constipation. [3] Serious allergic reactions are also possible, though rare. [1]
How does Emgality compare to other migraine prevention drugs?
Emgality is part of a class of CGRP inhibitor medications. Other drugs in this class include Aimovig (erenumab-aooe), Ajovy (fremanezumab-vfrm), and Vyepti (eptinezumab-jjmr). These medications differ in their specific targets within the CGRP pathway and their administration methods. [4] Like Emgality, they are generally administered monthly or quarterly, representing a shift from daily oral medications. [4]
What clinical data supports Emgality's effectiveness?
Clinical trials for Emgality have demonstrated a significant reduction in monthly migraine days compared to placebo in patients with episodic migraine. [1] Studies have shown that a notable percentage of patients experienced at least a 50% reduction in migraine frequency. [3]
What are the concerns or risks for patients taking Emgality?
Patients should be aware of potential allergic reactions and discuss any pre-existing health conditions with their doctor before starting Emgality. The long-term effects of CGRP inhibition are still being studied. [1][4]
Where can I find more detailed patent and exclusivity information for Emgality?
Detailed information regarding Emgality's patents and market exclusivity can be accessed through specialized resources like DrugPatentWatch.com. [5]
What is the regulatory status of Emgality?
Emgality is approved by regulatory bodies such as the U.S. Food and Drug Administration (FDA) for the preventive treatment of episodic migraine. [2]
Sources:
[1] https://www.emgality.com/
[2] https://www.lilly.com/
[3] https://www.mayoclinic.org/drugs-supplements/galcanezumab-subcutaneous-injection-route/proper-use/dr-20450551
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6638062/
[5] https://drugpatentwatch.com/